Residency · Residency · General Surgery

Colorectal Liver Metastases

Overview

The liver is the most common site of distant metastasis from colorectal cancer (CRC). Approximately 15 to 25% of CRC patients present with synchronous liver metastases, and up to 50% will develop metachronous disease during their course. Hepatic metastasectomy remains the only potentially curative treatment, achieving 5-year survival of 40 to 60%. A multidisciplinary tumor board (MDT) is essential for treatment planning.

Patient Selection and Workup

Imaging

The imaging workup begins with contrast-enhanced CT of the chest, abdomen, and pelvis for staging. Liver MRI with hepatocyte-specific contrast (gadoxetate/Eovist) is the most sensitive modality for detecting small lesions and should be obtained in all patients being considered for surgery. PET-CT is used to rule out extrahepatic disease, especially in patients with high clinical risk scores. At the time of surgery, intraoperative ultrasound (IOUS) remains the gold standard for detecting occult lesions and changes operative management in up to 30% of cases.

Resectability Criteria

Resectability is no longer defined by the number, size, or distribution of metastases. Modern criteria focus on the ability to achieve R0 resection of all disease, preservation of adequate future liver remnant (greater than 20% for normal liver, greater than 30% for chemotherapy-treated liver, greater than 40% for cirrhotic liver), preservation of adequate vascular inflow, outflow, and biliary drainage, and retention of at least two contiguous segments with adequate perfusion.

Clinical Risk Score (Fong/MSKCC)

The Fong clinical risk score assigns one point each for five criteria: node-positive primary tumor, disease-free interval less than 12 months, more than one metastasis, largest metastasis greater than 5 cm, and CEA greater than 200 ng/mL. A higher score predicts worse prognosis but does not preclude resection.

<image>Contrast-enhanced liver MRI showing multiple colorectal liver metastases with characteristic rim enhancement and central necrosis</image>

Neoadjuvant and Adjuvant Chemotherapy

Neoadjuvant Chemotherapy

Standard regimens include FOLFOX or FOLFIRI with or without a biologic agent (bevacizumab, or cetuximab for RAS wild-type tumors). Indications include initially unresectable disease being treated for conversion to resectability, borderline resectable disease, and as a test of tumor biology (progression on chemotherapy signals poor prognosis). The optimal duration is 2 to 3 months preoperatively (4 to 6 cycles). Prolonged chemotherapy should be avoided because hepatotoxicity increases -- oxaliplatin causes sinusoidal obstruction syndrome and irinotecan causes steatohepatitis.

Adjuvant Chemotherapy

Adjuvant treatment typically consists of FOLFOX for a total perioperative duration of 6 months (including the neoadjuvant component). The EORTC 40983 (EPOC) trial showed a trend toward improved progression-free survival with perioperative FOLFOX but no overall survival benefit.

Response Assessment

Radiologic response is assessed using RECIST criteria, and pathologic response (tumor regression grade) provides additional prognostic information. Disappearing metastases after chemotherapy are difficult to identify at surgery; lesions should be marked with clips before starting chemotherapy, or IOUS should be used to locate the original tumor sites.

Surgical Approaches

Resection Strategies

Both anatomic resection (segmentectomy, sectionectomy, hemihepatectomy) and non-anatomic (wedge) resection are options. Parenchymal-sparing hepatectomy (PSH) is preferred when possible because it preserves the future liver remnant for potential repeat hepatectomy and has been shown to achieve similar oncologic outcomes to major hepatectomy in multiple studies. Regarding margins, while a 1 cm margin was the traditional goal, current evidence supports an R0 margin of any width as adequate. An R1 vascular margin (tumor detachment from a major vessel) may also be acceptable.

Two-Stage Hepatectomy

For bilateral, extensive disease not amenable to single-stage resection, a two-stage hepatectomy can be performed. Stage 1 clears one hemiliver and is followed by portal vein embolization (PVE) or ligation of the contralateral side. After an interval of 4 to 8 weeks for liver hypertrophy, Stage 2 resects the remaining disease. The completion rate is approximately 70 to 80%.

ALPPS

ALPPS (Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy) achieves rapid hypertrophy of the future liver remnant, typically over 7 to 14 days between stages. However, it carries higher morbidity and mortality compared to the conventional two-stage approach and is reserved for cases where PVE-induced hypertrophy is insufficient.

<image>Diagram showing the two-stage hepatectomy approach with portal vein embolization between stages, illustrating compensatory hypertrophy of the future liver remnant</image>

Synchronous vs. Metachronous Presentation

For synchronous disease, three strategies exist. The simultaneous approach performs primary CRC resection and hepatic metastasectomy in the same operation, which is best suited for limited liver disease requiring only minor hepatectomy. The staged colon-first approach is the traditional strategy, allowing recovery between operations. The liver-first approach is used when the liver disease is symptomatic or threatening, with the primary tumor managed after liver surgery. The decision is based on symptoms, the extent of liver and colorectal disease, and patient fitness.

Ablation Techniques

Radiofrequency Ablation (RFA) and Microwave Ablation (MWA)

Ablation is used for unresectable disease, poor surgical candidates, or as an adjunct to resection for deep lesions in the contralateral lobe. Microwave ablation is increasingly preferred over RFA because it is faster, experiences less heat-sink effect, and creates larger ablation zones. Best outcomes are achieved for lesions smaller than 3 cm, with higher local recurrence rates for lesions exceeding 3 cm. A minimum 1 cm ablation margin around the tumor is recommended. Ablation can be performed percutaneously, laparoscopically, or via an open approach.

Other Modalities

Hepatic arterial infusion pump (HAIP) chemotherapy delivers floxuridine (FUDR) directly into the hepatic artery, and data from MSKCC shows improved outcomes in unresectable CLM. Stereotactic body radiation therapy (SBRT) is an option for oligometastatic disease in poor surgical candidates. Transarterial radioembolization (TARE/Y-90) and transarterial chemoembolization (TACE) are additional locoregional options, though TACE is less commonly used for CLM.

<image>Intraoperative ultrasound-guided microwave ablation of a colorectal liver metastasis with the ablation zone encompassing the tumor with adequate margins</image>

Management of Recurrence

Recurrence after initial hepatectomy occurs in 50 to 70% of patients. Repeat hepatectomy is safe and effective in selected patients and confers a similar survival benefit to the initial resection, with 5-year survival of 30 to 50%. A parenchymal-sparing approach at the initial resection facilitates repeat resection. Ablation can supplement or replace repeat resection when appropriate.

Extrahepatic Disease

Extrahepatic disease was historically considered a contraindication to hepatic metastasectomy. However, selected patients with limited, resectable extrahepatic disease (such as lung metastases or peritoneal carcinomatosis) may benefit from aggressive multimodal treatment. Pulmonary metastasectomy in selected patients achieves 5-year survival of 30 to 50%.

<image>Algorithm showing the multidisciplinary decision pathway for colorectal liver metastases from initial diagnosis through resectability assessment, neoadjuvant therapy, and surgical planning</image>

Clinical Pearls

Always obtain a liver MRI with hepatocyte-specific contrast, as CT alone misses up to 20% of lesions. Disappearing metastases on imaging after chemotherapy does not mean complete pathologic response; always attempt to identify and resect or ablate the original tumor sites. Prolonged neoadjuvant chemotherapy (more than 6 cycles) increases hepatotoxicity without improving oncologic outcomes -- operate when resectable. CEA is an imperfect marker, but a rising CEA postoperatively should prompt imaging. Intraoperative ultrasound changes management in up to 30% of cases and should always be performed. RAS mutation status affects prognosis and response to anti-EGFR therapy, so molecular profiling should be obtained on all patients.

References

• Fong Y, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer. Ann Surg. 1999;230(3):309-321.
• Nordlinger B, et al. Perioperative FOLFOX4 chemotherapy and surgery vs surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983). Lancet. 2008;371(9617):1007-1016.
• Adams RB, et al. Selection for hepatic resection of colorectal liver metastases: Expert consensus statement. HPB. 2013;15(2):91-103.
• Charnsangavej C, et al. Selection of patients for resection of hepatic colorectal metastases: Expert consensus statement. Ann Surg Oncol. 2006;13(10):1261-1268.
• Kemeny NE, et al. Hepatic arterial infusion pump chemotherapy for colorectal liver metastases. Lancet Oncol. 2021;22(10):e461-e474.

Read this lecture as Markdown